65320 Federal Register / Vol. 65, No. 212 / Wednesday, November 1, 2000 / Notices

On page 55256, in the State of

California, in the County of Fresno, in

the Funding to the following counties

column, delete ‘‘752,322’’ and replace

with ‘‘798,213’’.

On page 55256, in the State of

California, in the County of Nevada, in

the Funding to the following counties

column, delete ‘‘$1,077,655’’ and

replace with ‘‘$1,146,292’’.

On page 55256, in the State of

California, in the County of San Mateo,

in the Funding to the following counties

column, delete ‘‘$641,039’’ and replace

with ‘‘$1,072,738’’ and in the Current

service area column, delete ‘‘Half Moon

Bay’’ with replace with ‘‘Entire

County’’.

On page 55256, in the State of

Colorado, in the County of Denver, next

to the Funding amount of $1,380,779, in

the Current service area column, after

Montbello delete ‘‘and City Park’’ and

replace with ‘‘City Park, Globeville,

Skyland and North Capitol Hill’’.

On page 55257, in the State of Hawaii,

in the County of Oahu, in the Funding

for the following counties column,

delete ‘‘$635,745’’ and replace with

‘‘$678,925’’ and in the County of Oahu,

in the Funding for the following

counties column, delete ‘‘$453,443’’ and

replace with ‘‘$481,104’’.

On page 55257, in the State of Idaho,

add ‘‘Nez Perce’’ to the County Column,

and add ‘‘Nez Perce Reservation’’ in the

Current service area column.

On page 55259, in the State of New

York, in the County of Saratoga, in the

Funding for the following counties

column, delete ‘‘$998,746’’ and replace

with ‘‘$927,124’’.

On page 55259, in the State of North

Dakota, delete ‘‘Carson’’ from the

County column, delete ‘‘$797,487’’ from

the Funding for the following counties

column, and delete ‘‘Boundaries of

Standing Rock Reservation’’ from the

Current service area column.

On page 55259, in the State of North

Dakota, in the County of Sioux, add

‘‘$797,487’’ to the Funding for the

following counties column and delete

‘‘Boundaries of Standing Rock

Reservation’’ from the Current service

area column and replace with ‘‘Standing

Rock Sioux Reservation’’.

On page 55259, in the State of South

Dakota, in the County of Pennington, in

the Funding for the following counties

column, delete ‘‘$795,140’’ and replace

with ‘‘$1,155,140’’.

On page 55259, in the State of South

Dakota, in the County column, after

Meade, add the following County:

‘‘Lawrence’’ and in the Current service

area column add ‘‘Entire County’’.

On page 55259, in the State of South

Dakota, in the County column after

Lawrence, add the following County:

‘‘Fall River’’ and in the Current service

area column add ‘‘Entire County’’.

On page 55259, in the State of South

Dakota, in the County Column after

‘‘Fall River’’, add the following County:

‘‘Custer’’ and in the Current service area

column add ‘‘Entire County’’.

On page 55259, in the State of South

Dakota, in the County Column after

‘‘Custer’’, add the following County:

‘‘Jackson’’ and in the Current service

area column add ‘‘Entire County’’.

On page 55259, in the State of South

Dakota, in the County Column after

‘‘Jackson’’, add the following County:

‘‘Haakon’’ and in the Current service

area column add ‘‘Entire County’’.

On page 55259, in the State of South

Dakota, add ‘‘Corson’’ to the County

column, and in the Current service area

column add ‘‘Standing Rock Sioux

Reservation’’ and add the following note

in the Current service area column:

‘‘Note: for funding level see North

Dakota, Sioux County’’.

On page 55260, in the State of

Virginia, in the County of Buchanan, in

the Funding for the following counties

column, delete ‘‘$425,640’’ and replace

with ‘‘$657,534’’.

FOR FURTHER INFORMATION CONTACT: The

ACYF Operations Center at 1–800–351–

2293 or send an email to

chs@lcgnet.com. You can also contact

Judith Jerald, Early Head Start, Head

Start Bureau at (202) 205–8074.

Dated: October 24, 2000.

Patricia Montoya,

Commission, Administration on Children,

Youth and Families.

[FR Doc. 00–27970 Filed 10–31–00; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Request for Nominations for Members

on Public Advisory Committees;

Pharmacy Compounding Advisory

Committee

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is requesting

nominations for four members to serve

on the Pharmacy Compounding

Advisory Committee in the Center for

Drug Evaluation and Research.

FDA has special interest in ensuring

that women, minority groups, and the

physically challenged are adequately

represented on advisory committees

and, therefore, extends particular

encouragement to nominations for

appropriately qualified female,

minority, or physically challenged

candidates. Final selection from among

each vacancy will be determined by the

expertise required to meet specific

agency needs and in a manner to ensure

appropriate balance of membership.

DATES: Nominations should be received

on or before December 1, 2000.

ADDRESSES: All nominations for

membership should be sent to Jayne E.

Peterson (address below).

FOR FURTHER INFORMATION CONTACT:

Regarding all nominations for

membership: Jayne E. Peterson,

Center for Drug Evaluation and

Research (HFD–21), Food and Drug

Administration, 5600 Fishers Lane,

Rockville, MD 20857, 301–827–

7001.

SUPPLEMENTARY INFORMATION: On

November 21, 1997, the President

signed the Food and Drug

Administration Modernization Act of

1997 (Public Law 105–115) (the

Modernization Act). Section 127 of the

Modernization Act added section 503A

to the Federal Food, Drug, and Cosmetic

Act (the act) (21 U.S.C. 353a)). Section

503A of the act directs FDA to issue

regulations relating to the application of

Federal law to the practice of pharmacy

compounding. To assist the agency in

preparing these regulations, Congress

directed FDA to convene and consult an

advisory committee that will include

representatives of the National

Association of Boards of Pharmacy

(NABP), the United States

Pharmacopeia (USP), pharmacy,

physician and consumer organizations,

as well as other experts selected by the

agency. The Pharmacy Compounding

Advisory Committee was formed on

March 10, 1998, and 15 members were

appointed to the committee. The terms

of four members have expired or the

positions have otherwise become

vacant. Accordingly, FDA is requesting

nominations for four members to serve

on the Pharmacy Compounding

Advisory Committee.

Function

The function of the committee is to

provide advice on scientific, technical,

and medical issues concerning drug

compounding by licensed practitioners

and to make appropriate

recommendations to the Commissioner

of Food and Drugs.

Criteria for Members

Persons nominated for membership

should have expertise in one or more of

the following fields: Pharmaceutical

Federal Register / Vol. 65, No. 212 / Wednesday, November 1, 2000 / Notices 65321

compounding, the practices of

pharmacies specializing in

compounding, the practices of general

retail pharmacies, the practices of

hospital pharmacies, fields of medicine

in which compounding drugs or the use

of compounded drugs is relatively

common, pharmaceutical

manufacturing, clinical toxicology,

clinical pharmacology, chemistry, and

related specialties. The current

committee includes one representative

of the NABP, one representative of the

USP, one representative of a consumer

organization, and one representative of

the pharmaceutical manufacturing

industry whose terms have not yet

expired. The term of office is up to 4

years.

Nomination Procedures

Interested persons may nominate one

or more qualified persons for

membership on the advisory committee.

Nominations shall state that the

nominee is willing to serve as a member

of the advisory committee and appears

to have no conflict of interest that

would preclude committee membership.

Potential candidates will be asked by

FDA to provide detailed information

concerning such matters as financial

holdings, consultancies, and research

grants or contracts to permit evaluation

of possible sources of conflict of

interest.

This notice is issued under the

Federal Advisory Committee Act (5

U.S.C. app. 2), section 503A of the

Federal Food, Drug, and Cosmetic Act

(21 U.S.C. 353a), section 904 of the

Federal Food, Drug, and Cosmetic Act

(21 U.S.C. 394) as amended by the Food

and Drug Administration Revitalization

Act (Public Law 101–635), and 21 CFR

part 14, relating to advisory committees.

Dated: October 25, 2000.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 00–27966 Filed 10–31–00; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Substance Abuse and Mental Health

Services Administration

Current List of Laboratories Which

Meet Minimum Standards To Engage in

Urine Drug Testing for Federal

Agencies

AGENCY: Substance Abuse and Mental

Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and

Human Services notifies Federal

agencies of the laboratories currently

certified to meet standards of Subpart C

of Mandatory Guidelines for Federal

Workplace Drug Testing Programs (59

FR 29916, 29925). A similar notice

listing all currently certified laboratories

will be published during the first week

of each month, and updated to include

laboratories which subsequently apply

for and complete the certification

process. If any listed laboratory’s

certification is totally suspended or

revoked, the laboratory will be omitted

from updated lists until such time as it

is restored to full certification under the

Guidelines.

If any laboratory has withdrawn from

the National Laboratory Certification

Program during the past month, it will

be listed at the end, and will be omitted

from the monthly listing thereafter.

This Notice is also available on the

internet at the following website: http:/

/www.health.org/workplace.

FOR FURTHER INFORMATION CONTACT: Mrs.

Giselle Hersh or Dr. Walter Vogl,

Division of Workplace Programs, 5600

Fishers Lane, Rockwall 2 Building,

Room 815, Rockville, Maryland 20857;

Tel.: (301) 443–6014, Fax: (301) 443–

3031.

Special Note: Please use the above address

for all surface mail and correspondence. For

all overnight mail service use the following

address: Division of Workplace Programs,

5515 Security Lane, Room 815, Rockville,

Maryland 20852.

SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal

Workplace Drug Testing were developed

in accordance with Executive Order

12564 and section 503 of Pub. L. 100–

71. Subpart C of the Guidelines,

‘‘Certification of Laboratories Engaged

in Urine Drug Testing for Federal

Agencies,’’ sets strict standards which

laboratories must meet in order to

conduct urine drug testing for Federal

agencies. To become certified an

applicant laboratory must undergo three

rounds of performance testing plus an

on-site inspection. To maintain that

certification a laboratory must

participate in a quarterly performance

testing program plus periodic, on-site

inspections.

Laboratories which claim to be in the

applicant stage of certification are not to

be considered as meeting the minimum

requirements expressed in the HHS

Guidelines. A laboratory must have its

letter of certification from SAMHSA,

HHS (formerly: HHS/NIDA) which

attests that it has met minimum

standards.

In accordance with Subpart C of the

Guidelines, the following laboratories

meet the minimum standards set forth

in the Guidelines:

ACL Laboratories, 8901 W. Lincoln

Ave., West Allis, WI 53227, 414–328–

7840/800–877–7016, (Formerly:

Bayshore Clinical Laboratory).

Advanced Toxicology Network, 3560

Air Center Cove, Suite 101, Memphis,

TN 38118, 901–794–5770/888–290–

1150.

Aegis Analytical Laboratories, Inc., 345

Hill Ave., Nashville, TN 37210, 615–

255–2400.

Alabama Reference Laboratories, Inc.,

543 South Hull St., Montgomery, AL

36103, 800–541–4931/334–263–5745.

Alliance Laboratory Services, 3200

Burnet Ave., Cincinnati, OH 45229,

513–585–9000, (Formerly: Jewish

Hospital of Cincinnati, Inc.).

American Medical Laboratories, Inc.,

14225 Newbrook Dr., Chantilly, VA

20151, 703–802–6900.

Associated Pathologists Laboratories,

Inc., 4230 South Burnham Ave., Suite

250, Las Vegas, NV 89119–5412, 702–

733–7866/800–433–2750.

Baptist Medical Center—Toxicology

Laboratory, 9601 I–630, Exit 7, Little

Rock, AR 72205–7299, 501–202–2783

(Formerly: Forensic Toxicology

Laboratory Baptist Medical Center)

Clinical Laboratory Partners, LLC, 129

East Cedar St., Newington, CT 06111,

860–696–8115 (Formerly: Hartford

Hospital Toxicology Laboratory)

Clinical Reference Lab, 8433 Quivira

Rd., Lenexa, KS 66215–2802, 800–

445–6917

Cox Health Systems, Department of

Toxicology, 1423 North Jefferson

Ave., Springfield, MO 65802, 800–

876–3652/417–269–3093 (Formerly:

Cox Medical Centers)

Dept. of the Navy, Navy Drug Screening

Laboratory, Great Lakes, IL, Building

38–H, P.O. Box 88–6819, Great Lakes,

IL 60088–6819, 847–688–2045/847–

688–4171

Diagnostic Services Inc., dba DSI, 12700

Westlinks Drive, Fort Myers, FL

33913, 941–561–8200/800–735–5416

Doctors Laboratory, Inc., P.O. Box 2658,

2906 Julia Dr., Valdosta, GA 31602,

912–244–4468

DrugProof, Division of Dynacare/

Laboratory of Pathology, LLC, 1229

Madison St., Suite 500, Nordstrom

Medical Tower, Seattle, WA 98104,

206–386–2672/800–898–0180

(Formerly: Laboratory of Pathology of

Seattle, Inc., DrugProof, Division of

Laboratory of Pathology of Seattle,

Inc.)

DrugScan, Inc., P.O. Box 2969, 1119

Mearns Rd., Warminster, PA 18974,

215–674–9310

Dynacare Kasper Medical Laboratories,*

14940–123 Ave., Edmonton, Alberta,